|
Antimicrobial agent
|
No. of very major errors
|
No. of major errors
|
No. of minor errors
|
AST agreement
|
Total
|
|---|
|
A
|
|
Cefotaxime (CTX)
|
0/40
|
1/19 (5.3 %)
|
2/59 (3.4 %)
|
56 (94.9 %)
|
59
|
|
Ceftazidime (CAZ)
|
0/32
|
10/25 (40 %)
|
4/60 (6.7 %)
|
46 (76.7 %)
|
60
|
|
Gentamicin (GM)
|
0/24
|
10/35 (28.6 %)
|
2/61 (3.3 %)
|
49 (80.3 %)
|
61
|
|
Levofloxacin (LEV)
|
0/34
|
0/26 (0 %)
|
0/60
|
60 (100 %)
|
60
|
|
Meropenem (MEM)
|
0/18
|
5/43 (11.6 %)
|
2/61 (3.3 %)
|
54 (88.5 %)
|
61
|
|
Total (%)
|
0/148
|
26/148 (17.6 %)
|
10/301 (3.3 %)
|
265 (88.1 %)
|
301
|
|
B
|
|
Cefotaxime (CTX)
|
6/39 (15.4 %)
|
0/19
|
0/58
|
52 (89.7 %)
|
58
|
|
Ceftazidime (CAZ)
|
0/31
|
1/24 (4.2 %)
|
3/58 (5.2 %)
|
54 (93.1 %)
|
58
|
|
Gentamicin (GM)
|
0/25
|
8/33 (24.2 %)
|
1/60 (1.7 %)
|
51 (85 %)
|
60
|
|
Levofloxacin (LEV)
|
0/34
|
0/24
|
0/58
|
58 (100 %)
|
58
|
|
Meropenem (MEM)
|
0/16
|
6/42 (14.3 %)
|
2/58 (3.5 %)
|
50 (86.2 %)
|
58
|
|
Total (%)
|
6/145 (4.1 %)
|
15/142 (10.6 %)
|
6/292 (2.1 %)
|
265 (90.7 %)
|
292
|
-
aUsing the results from the susceptibility testing of the bacteria by Vitek 2 as reference. In case of discrepancies between the two methods, the results for the susceptibility testing were confirmed by E-test. Data are numbers (with percentages) of bacterial isolates for which the antimicrobial susceptibility testing was concordant/correct or erroneous by PR1 (A) or PR2 (B)
